Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Aug 11.

Published in final edited form as: J Clin Exp Oncol. 2013;2(2):1000109.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

PMC Copyright notice

Influence on the cytotoxic anti-neoplastic potency of gemcitabine-(C₄-amide)-[anti-HER2/neu] when applied in dual combination with mebendazole against chemotherapeutic-resistant human mammary adenocarcinoma. Legends: (■) covalent gemcitabine-(C₄-amide)-[anti-HER2/neu] immunochemotherapeutic and mebendazole; (◆) covalent gemcitabine-(C₄-amide)-[anti-HER2/neu] immunochemotherapeutic; and (▲) gemcitabine with mebendazole Chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated with gemcitabine-(C₄-amide)-[anti-HER2/neu] formulated in triplicate at gradient concentrations (+/- mebendazole 0.15 μM fixed-concentration). Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.